HepG2 Transfection Reagent (Hepatocellular Carcinoma)
Transfection Reagent for HepG2 Cells (Hepatocellular Carcinoma Cells, HB-8065)
- Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Effective and robust intracellular delivery
Kit includes Transfection Enhancer reagent
Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
Work in the presence of serum
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems HepG2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
HepG2 Cell Line:
HepG2 was derived from the liver tissue of a 15 year-old male with differentiated hepatocellular carcinoma. These cells are epithelial and have model chromosome number of 55. The cells secrete a variety of major plasma proteins such as albumin, transferrin, alpha 1-antitrypsin, alpha 2-macroglobulin, and plasminogen (they have been grown successfully in large scale cultivation systems). The cells are responsive to stimulation with human growth hormone. HepG2 cells have also been shown to be resistant to G418. HepG2 cells and its derivatives are used as a model system for studies of liver metabolism and toxicity of xenobiotics, anti genotoxic and cogenotoxic agents, understanding hepatocarcinogenesis, the detection of cytoprotective, and for drug targeting studies. HepG2 cells are also employed in trials with bio-artificial liver devices. This cell line is widely used in human cancer research of the liver, and could be useful for many different types of biomedical research. HepG2 cells produce albumin, transferrin, fibrinogen, plasminogen, and respond to human growth hormone (hGH).
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the HepG2 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, elecroporation kits, and in vivo delivery reagents (peg-liposome, nanoparticle, lipid, and polymer-based; and tissue targeted: liver, pancreas, kidney). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen's Transfection Resource.
Altogen Research Services:
Altogen Labs is a GLP compliant laboratory that provides preclinical contract research services (CRO). Pharma and biotechnology services include: transient and stable transfection (development of stable cell lines), liposome encapsulation (proteins, DNA, mRNA, siRNA), A-to-Z RNAi services, in vivo and in vitro toxicology, xenograft animal models, assay development, cell banking and cryopreservation services.